In this study [71], PDOs were generated from cancer patients enrolled in Phase 1/2 clinical trials and drug responses (anti-EGFR monoclonal antibodies, regorafenib, and TAS-102) were evaluated both ex vivo and in PDO-derived xenografts. The gene discussed is EGFR; the disease is cancer.